Hematology

Up to a quarter of patients with classical Hodgkin’s lymphoma (HL) are resistant or have disease relapse after first-line chemotherapy…

The ‘Mastering the Relapsed Refractory Multiple Myeloma (RRMM) Treatment Landscape: Removing Barriers and Unleashing the Potential of…

Talha Munir reviews the recent developments in chronic lymphocytic leukaemia research presented at the 2024 American Society of Hematology…

Acute myeloid leukaemia (AML) is a rapidly progressing myeloid neoplasm caused by the clonal expansion of primitive haematopoietic stem…

This review article explores key research highlights and new data on CLL presented at EHA 2025, considering how the latest clinical…

Since research on human gene therapy began, the expectations regarding its potential in treating haemophilia have been high. Haemophilia…

TEST In this feature, the authors critically analyse the European standards for Haemophilia Treatment Centres (HTC), examining their…

Rituximab, a monoclonal anti-CD20 antibody, has proven to be an excellent therapeutic agent for haematological diseases. Low-dose…